PT-141 (Bremelanotide): What the Phase 3 Trials Actually Showed
PT-141 is one of the few research peptides that completed randomised phase 3 trials. What those trials found, what an independent re-analysis disputes, and what the safety record really says.
Important notice: This article is for scientific information and research purposes only. PT-141 is a research peptide, not intended for human consumption, and it holds no EU marketing authorisation. Nothing here is a dosing recommendation or a protocol. Doses are cited only to describe what published studies administered.
TL;DR: an unusually well-studied peptide, and an unusually contested one
What it is: A cyclic seven-amino-acid melanocortin receptor agonist, chemically the free-acid form of Melanotan-II and its identified active metabolite. Why it stands out: Almost no compound in this category has completed randomised, placebo-controlled phase 3 trials. Bremelanotide has, in 1267 participants (PMID 31599840). The honest complication: An independent 2021 re-analysis reproduced the efficacy numbers but criticised selective outcome reporting and found far higher adverse-event discontinuation than placebo (PMID 33678061). The mechanism caveat: Preclinical work implicates MC4R-linked neural pathways. The mechanism behind the human trial results is not established. The safety headline: Nausea in 40.0% versus 1.3% on placebo, and nausea was the leading reason participants stopped (PMID 35147466).
Cyclic heptapeptide (bremelanotide) that acts as a melanocortin receptor agonist at MC3R and MC4R in the central nervous system. The active metabolite of Melanotan-II, studied for sexual-function endpoints via a central rather than vascular pathway.
What PT-141 actually is
PT-141, also called bremelanotide, is a synthetic cyclic peptide of seven amino acids arranged in a ring. It comes out of melanocortin research at the University of Arizona and was developed further by Palatin Technologies.
Its relationship to Melanotan-II is the single most misdescribed fact about it. PT-141 is not a fragment of Melanotan-II, and no peptide bond is cleaved to produce it. The two molecules carry the same seven residues. The difference is at the C-terminus: Melanotan-II is amidated, and in bremelanotide that amide is hydrolysed to a free carboxylic acid. Bremelanotide was identified as the metabolite of Melanotan-II that stays active at melanocortin receptors.
Three different molecules, routinely confused
Bremelanotide, Melanotan-II and afamelanotide are three distinct chemical entities with different receptor profiles, different development histories and different regulatory status. Afamelanotide is a linear 13-residue alpha-MSH analogue (NDP-alpha-MSH), and Melanotan-II was developed by truncating and cyclising that scaffold, with bremelanotide being the free-acid form of Melanotan-II. So the three share a lineage but are chemically distinct, with different receptor pharmacology, evidence and regulatory status. Findings for one should never be transferred to the others.
How it is thought to work
The melanocortin system is a family of five receptors, MC1R through MC5R, sitting at the centre of several regulatory circuits: pigmentation, inflammation, energy balance and sexual function. Bremelanotide is a non-selective agonist across that family, and research attention concentrates on MC3R and MC4R.
The contrast the literature keeps drawing is with PDE5-targeting compounds, which act on vascular smooth muscle and change blood flow. Bremelanotide is not that kind of mechanism. A widely cited 2002 mouse study used the non-peptide MC4R agonist THIQ and found effects consistent with neural circuitry rather than direct action on penile smooth muscle (PMID 12172010). A 2003 overview from the developing company described activity at MC3R and MC4R together with hypothalamic neuronal activation in rats after systemic administration (PMID 12851303).
What is established and what is not
Established: bremelanotide binds and activates melanocortin receptors, and it is not a PDE5 mechanism. Not established: the mechanism responsible for the effects observed in the human trials. The central, MC4R-linked pathway is the leading hypothesis drawn from animal work, not a demonstrated human mechanism. The approved product's own labelling describes the mechanism as unknown.
Animal evidence is also not unanimous. A 2025 study in female Syrian hamsters mapped MC3R and MC4R onto midbrain dopamine neurons and reported that bremelanotide did not change receptor expression or sexual reward in that model (PMID 39793696). Negative results like this rarely make it into vendor copy, which is exactly why they are worth reading.
The clinical programme: what the trials administered and found
Two identical phase 3, randomised, double-blind, placebo-controlled multicentre trials, known together as RECONNECT, randomised 1267 premenopausal participants. Participants self-administered 1.75 mg of bremelanotide subcutaneously on an as-needed basis over 24 weeks of treatment, and both co-primary endpoints were met (PMID 31599840).
Earlier work maps the dose range that led there. A dose-finding trial tested 0.75, 1.25 and 1.75 mg subcutaneously, self-administered as desired over 12 weeks (PMID 27181790). Earlier still, single subcutaneous doses from 0.3 mg up to 10 mg were given to healthy men, with a significant erectile response reported above roughly 1 mg (PMID 14999221). The original programme also investigated intranasal administration before the injectable route was taken forward (PMID 14963471).
These are trial regimens, not protocols
Every figure above describes what a clinical trial administered under medical supervision as part of drug development. None of it is an approved or public protocol, and none of it applies to research material, which is not for human use.
Participants who completed the 24-week double-blind phase could enter a 52-week open-label extension (PMID 31599847). That extension had no placebo control, its analyses were descriptive, and attrition was heavy: of 684 who enrolled, only 272 completed. It supports a statement about sustained tolerability, not a controlled efficacy claim.
The independent re-analysis, and why it matters
This is the part most product pages leave out. In 2021, an independent re-analysis of the phase 3 data was published (PMID 33678061). It did not claim the sponsor fabricated results: it reproduced the efficacy estimates from the regulatory submission. Its criticism was about selective outcome reporting, about the validity of the measures used, and about the balance of benefit against harm, noting substantially higher adverse-event-driven discontinuation on bremelanotide than on placebo.
A separate and independent systematic review with meta-analysis of treatment options was published in 2026 (PMID 40543759), which is useful precisely because it is not sponsor-generated.
Reading sponsored evidence honestly
The pivotal trials, the long-term extension and the integrated safety analysis were all sponsor-funded, with company employees among the authors. That does not make them wrong, and they remain the best-controlled data that exist for this compound. It does mean that an independent re-analysis and an independent meta-analysis belong next to them rather than being quietly omitted.
The safety record
The integrated safety analysis across the clinical development programme is the most useful single source here (PMID 35147466). In the integrated double-blind phase 3 portion, with 1247 participants, the most common adverse events were:
- Nausea: 40.0% versus 1.3% on placebo
- Flushing: 20.3% versus 1.3%
- Headache: 11.3% versus 1.9%
- Injection site reactions: 5.4% versus 0.5%
Nausea was the leading reason participants discontinued. Transient increases in blood pressure have also been documented, which is why the approved United States product carries restrictions against use in uncontrolled hypertension and known cardiovascular disease.
Pigmentation is reduced, not absent
Melanotan-II has strong MC1R activity, and MC1R drives pigmentation. Bremelanotide shows comparatively less of that activity, which is a real difference, but it is not a clean separation: focal hyperpigmentation was reported in the clinical development programme after repeated daily dosing well above the approved as-needed regimen (PMID 35147466).
Regulatory status
Bremelanotide holds a marketing authorisation in the United States for a specific indication in premenopausal women. There is no EU marketing authorisation. That combination is unusual for this category and it cuts both ways: the compound has a real controlled evidence base behind it, and at the same time nothing sold as a research material is that authorised medicine or interchangeable with it.
Tanning peptide that activates melanin production in the skin. Stimulates melanocyte receptors for natural UV-free pigmentation. Also researched for appetite regulation and libido effects.
Why identity and purity are the practical question
For a compound with this much published pharmacology, the variable a researcher can actually control is the material itself. Chromatographic purity and measured content per vial are what a batch-specific third-party report establishes, and a report number that can be checked directly with the testing laboratory is what separates documentation from a claim.
How we handle this
Our batch documentation is produced by Janoshik, an independent analytical laboratory, and the testing is commissioned through the supply chain rather than by us. We publish the full report and its task number so it can be verified with the lab directly. We do not describe that as our own independent testing, because it is not.
Frequently asked questions
Related reading
Melanocortin receptor research, the parent compound
Growth hormone secretagogues and gonadotropins
Research use only. The material described here is supplied strictly for in-vitro research and laboratory use. It is not intended for human or animal consumption, nor for medical, cosmetic or household applications. Nothing in this article is a dosing recommendation, a protocol, or medical advice.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.